PMC:7799378 / 24023-26873 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T194","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"T195","span":{"begin":61,"end":174},"obj":"Sentence"},{"id":"T196","span":{"begin":175,"end":363},"obj":"Sentence"},{"id":"T197","span":{"begin":364,"end":416},"obj":"Sentence"},{"id":"T198","span":{"begin":417,"end":581},"obj":"Sentence"},{"id":"T199","span":{"begin":582,"end":723},"obj":"Sentence"},{"id":"T200","span":{"begin":724,"end":819},"obj":"Sentence"},{"id":"T201","span":{"begin":820,"end":919},"obj":"Sentence"},{"id":"T202","span":{"begin":920,"end":1073},"obj":"Sentence"},{"id":"T203","span":{"begin":1074,"end":1196},"obj":"Sentence"},{"id":"T204","span":{"begin":1197,"end":1330},"obj":"Sentence"},{"id":"T205","span":{"begin":1331,"end":1442},"obj":"Sentence"},{"id":"T206","span":{"begin":1443,"end":1578},"obj":"Sentence"},{"id":"T207","span":{"begin":1579,"end":1678},"obj":"Sentence"},{"id":"T208","span":{"begin":1679,"end":1802},"obj":"Sentence"},{"id":"T209","span":{"begin":1803,"end":1930},"obj":"Sentence"},{"id":"T210","span":{"begin":1931,"end":2036},"obj":"Sentence"},{"id":"T211","span":{"begin":2037,"end":2139},"obj":"Sentence"},{"id":"T212","span":{"begin":2140,"end":2234},"obj":"Sentence"},{"id":"T213","span":{"begin":2235,"end":2387},"obj":"Sentence"},{"id":"T214","span":{"begin":2388,"end":2504},"obj":"Sentence"},{"id":"T215","span":{"begin":2505,"end":2701},"obj":"Sentence"},{"id":"T216","span":{"begin":2702,"end":2850},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Potential influence of G6PD deficiency on COVID-19 therapies\nChloroquine (CQ), a 4-aminoquinoline drug, is commonly used in the treatment of malaria and amoebiasis [122,123]. It is also used for treating autoimmune diseases, including lupus erythematosus and rheumatoid arthritis, due to its capacity for modulating inflammation and the immune response [124,125]. The effect of CQ on certain viruses is inconclusive. A positive response is observed with CQ in chikungunya, HIV, and HCV infections [126–129], whereas it is not effective in influenza and dengue infections [126,130]. Hydroxychloroquine (HCQ) is a derivative of chloroquine and its treatment for COVID-19 is currently being evaluated in clinical trials [131]. The potential use of HCQ against COVID-19 may raise safety issues in certain populations [132]. Recent reports suggest that CQ or HCQ is possibly linked to hemolysis in G6PD deficiency [133–135]. However, two large retrospective studies indicated that no episode of hemolysis was found after HCQ treatment among G6PD-deficient individuals [136,137]. Hence, the claim that oxidant hemolysis due to chloroquine exposure in G6PD-deficient individuals remains unsettled [138].\nDespite the efforts of developing vaccines against COVID-19, studies show that the elderly are less responsive to immune stimulation. During aging, the depletion of naïve T cells and B cells weakens the immune defense against invading pathogens. Moreover, chronic and low-grade inflammation in the elderly, known as inflammaging, leads to a reduced ability to external stimulation. These events result in an impaired response to infection and dampen the reaction to vaccines [139]. Nevertheless, some anti-aging therapies show promising results related to enhancing the anti-viral response in the elderly. An mTOR inhibitor reduces infection, improves vaccination responses, and enhances the anti-viral response in the elderly [140]. Metformin is a common diabetic drug that indirectly inhibits mTOR and extends life span in animals [141]. The mortality rate drops in hospitalized patients with COVID-19 who have received metformin [142,143]. Senolytic drugs reduce inflammation and selectively remove senescent cells during aging [144]. These anti-aging compounds can exert their function in promoting healthspan by maintaining redox homeostasis and alleviating oxidative stress [145–147]. These compounds administered to the elderly with COVID-19 may reduce their mortality and improve recovery [148–151]. This opens the possibility of reducing the signs of aging or immunosenescence in the elderly population with drugs such as calorie restriction mimetics and senolytics before vaccination [152,153]. In particular, the elderly with G6PD deficiency may benefit from these treatments through boosting their antioxidative defense and immune responses."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T43","span":{"begin":204,"end":223},"obj":"Phenotype"},{"id":"T44","span":{"begin":259,"end":279},"obj":"Phenotype"},{"id":"T45","span":{"begin":979,"end":999},"obj":"Phenotype"},{"id":"T46","span":{"begin":2360,"end":2376},"obj":"Phenotype"}],"attributes":[{"id":"A43","pred":"hp_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A44","pred":"hp_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A45","pred":"hp_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/HP_0004802"},{"id":"A46","pred":"hp_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/HP_0025464"}],"text":"Potential influence of G6PD deficiency on COVID-19 therapies\nChloroquine (CQ), a 4-aminoquinoline drug, is commonly used in the treatment of malaria and amoebiasis [122,123]. It is also used for treating autoimmune diseases, including lupus erythematosus and rheumatoid arthritis, due to its capacity for modulating inflammation and the immune response [124,125]. The effect of CQ on certain viruses is inconclusive. A positive response is observed with CQ in chikungunya, HIV, and HCV infections [126–129], whereas it is not effective in influenza and dengue infections [126,130]. Hydroxychloroquine (HCQ) is a derivative of chloroquine and its treatment for COVID-19 is currently being evaluated in clinical trials [131]. The potential use of HCQ against COVID-19 may raise safety issues in certain populations [132]. Recent reports suggest that CQ or HCQ is possibly linked to hemolysis in G6PD deficiency [133–135]. However, two large retrospective studies indicated that no episode of hemolysis was found after HCQ treatment among G6PD-deficient individuals [136,137]. Hence, the claim that oxidant hemolysis due to chloroquine exposure in G6PD-deficient individuals remains unsettled [138].\nDespite the efforts of developing vaccines against COVID-19, studies show that the elderly are less responsive to immune stimulation. During aging, the depletion of naïve T cells and B cells weakens the immune defense against invading pathogens. Moreover, chronic and low-grade inflammation in the elderly, known as inflammaging, leads to a reduced ability to external stimulation. These events result in an impaired response to infection and dampen the reaction to vaccines [139]. Nevertheless, some anti-aging therapies show promising results related to enhancing the anti-viral response in the elderly. An mTOR inhibitor reduces infection, improves vaccination responses, and enhances the anti-viral response in the elderly [140]. Metformin is a common diabetic drug that indirectly inhibits mTOR and extends life span in animals [141]. The mortality rate drops in hospitalized patients with COVID-19 who have received metformin [142,143]. Senolytic drugs reduce inflammation and selectively remove senescent cells during aging [144]. These anti-aging compounds can exert their function in promoting healthspan by maintaining redox homeostasis and alleviating oxidative stress [145–147]. These compounds administered to the elderly with COVID-19 may reduce their mortality and improve recovery [148–151]. This opens the possibility of reducing the signs of aging or immunosenescence in the elderly population with drugs such as calorie restriction mimetics and senolytics before vaccination [152,153]. In particular, the elderly with G6PD deficiency may benefit from these treatments through boosting their antioxidative defense and immune responses."}

PMC:7799378 / 24023-26873 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-sentences

LitCovid-PD-HP

PMC:7799378 / 24023-26873 JSON TXT